159 related articles for article (PubMed ID: 12046381)
1. [The gastric mucigenous function in the treatment of patients with ulcer with various antisecretory preparations].
Vakhrushev IaM; Muravtseva OV
Eksp Klin Gastroenterol; 2002; (2):29-31, 101. PubMed ID: 12046381
[TBL] [Abstract][Full Text] [Related]
2. [The clinical effectiveness of rabeprazole in patients with acid-related gastric and duodenal diseases with various sensitivity of different types of parietal gastric cell receptors].
Serebrova SIu
Klin Med (Mosk); 2007; 85(3):61-4. PubMed ID: 17523409
[TBL] [Abstract][Full Text] [Related]
3. [Complex evaluation of the action of inhibitors of hydrochloric acid secretion on gastric function in ulcer disease].
Vakhrushev IaM; Muravtseva OV
Ter Arkh; 2006; 78(2):35-8. PubMed ID: 16613094
[TBL] [Abstract][Full Text] [Related]
4. [Comparative antisecretory activity of famotidine, omeprazole, and rabeprazole (pariet) in ulcer disease based on daily pH-monitoring].
Rakov AL; Makarov IuS; Gorbakov VV; Mironenko DA; Golochalova TV
Voen Med Zh; 2001 Sep; 322(9):54-8. PubMed ID: 11668793
[No Abstract] [Full Text] [Related]
5. [H2 receptor antagonists and proton pump inhibitors: principles and rules of use].
Bardou M
Rev Prat; 2001 Apr; 51(7):789-95. PubMed ID: 11387678
[No Abstract] [Full Text] [Related]
6. [Concerning the discussion article by I. A. Morozov "Choice of the gastroenterologist"].
Gorshkov VA
Klin Med (Mosk); 2002; 80(9):66-70. PubMed ID: 12416232
[No Abstract] [Full Text] [Related]
7. [Antisecretory therapy strategy for patients with bleeding and perforated gastroduodenal ulcers].
Evseev MA; Ivakhov GB; Golovin RA
Khirurgiia (Mosk); 2009; (3):46-52. PubMed ID: 19391208
[No Abstract] [Full Text] [Related]
8. [Double-blind controlled-clinical trials of lansoprazole in the treatment of peptic ulcer].
Ogawa N
Nihon Rinsho; 1992 Jan; 50(1):68-73. PubMed ID: 1347332
[TBL] [Abstract][Full Text] [Related]
9. [Antisecretory effects of quamatel and gastrocepin in duodenal ulcer: comparison with intragastric pH-metry].
Sheptulin AA; Okhlobystin AV
Klin Med (Mosk); 1998; 76(8):38-40. PubMed ID: 9770967
[TBL] [Abstract][Full Text] [Related]
10. Progress with proton pump inhibitors in acid peptic disease: treatment of duodenal and gastric ulcer.
Florent C
Clin Ther; 1993; 15 Suppl B():14-21. PubMed ID: 7911399
[TBL] [Abstract][Full Text] [Related]
11. Prolonged gastric pH monitoring in responder and nonresponder duodenal ulcer patients: response to placebo and to H2-blocker administration.
Masoero G; Rossanino A; Arossa W; De la Pierre M
J Clin Gastroenterol; 1991 Jun; 13(3):291-5. PubMed ID: 1676715
[TBL] [Abstract][Full Text] [Related]
12. Effects of ranitidine on quality of gastric ulcer healing compared with famotidine: a randomized, controlled, multicenter trial.
Higuchi K; Watanabe T; Tominaga K; Shiba M; Nakagawa K; Uno H; Kitada K; Satoh H; Chono S; Uchida T; Fujiwara Y; Arakawa T
Int J Clin Pharmacol Res; 2005; 25(4):187-94. PubMed ID: 16402635
[TBL] [Abstract][Full Text] [Related]
13. [Antisecretory therapy as a component of hemostasis in acute gastroduodenal ulcer bleedings].
Gostishchev VK; Evseev MA
Khirurgiia (Mosk); 2005; (8):52-7. PubMed ID: 16091681
[TBL] [Abstract][Full Text] [Related]
14. Do anticholinergics interact with histamine H2 receptor antagonists on night intragastric acidity in active duodenal ulcer patients?
Fiorucci S; Clausi GG; Farinelli M; Santucci L; Farroni F; Pelli MA; Morelli A
Am J Gastroenterol; 1988 Dec; 83(12):1371-5. PubMed ID: 2904218
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the effects of gastric antisecretory agents in healthy volunteers and patients with duodenal ulcer.
Howden CW; Jones DB; Burget DW; Hunt RH
Gut; 1986 Sep; 27(9):1058-61. PubMed ID: 3758819
[TBL] [Abstract][Full Text] [Related]
16. [Antisecretory and mucosa-protecting drugs in the acute care of peptic ulcer. Review of action principles, healing rates and side effects of approved ulcer drugs and drugs under clinical trial].
Simon B; Müller P; Dammann HG
Fortschr Med; 1984 Jul; 102(25-26):683-7. PubMed ID: 6147304
[TBL] [Abstract][Full Text] [Related]
17. Continuous 24-hour intragastric pH monitoring in the evaluation of the effect of a nightly dose of famotidine, ranitidine and placebo on gastric acidity of patients with duodenal ulcer.
Savarino V; Mela GS; Scalabrini P; Di Timoteo E; Magnolia MR; Celle G
Digestion; 1987; 37(2):103-9. PubMed ID: 3305114
[TBL] [Abstract][Full Text] [Related]
18. Effects of H2 blockers and omeprazole on peptic secretion: a prospective, randomized study in duodenal ulcer subjects.
Di Mario F; Dotto P; Vianello F; Germanà B; Grassi SA; Del Favero G; Faggian D; Plebani M; Naccarato R
Acta Gastroenterol Belg; 1993; 56(2):223-8. PubMed ID: 8103616
[TBL] [Abstract][Full Text] [Related]
19. [Acid anti-secretion therapy in gastric and duodenal ulcer].
Lattanzi A
Clin Ter; 1981 Oct; 99(2):187-205. PubMed ID: 6119184
[No Abstract] [Full Text] [Related]
20. Effects of changing the type of H2-blocker in the treatment of H2-blocker-resistant ulcers: comparison of roxatidine acetate hydrochloride and other H2-blockers.
Yasutake K; Amano M; Mizokami Y; Kubota S; Fukumoto H; Imamura Y; Yokoya H; Irie K
J Int Med Res; 1998; 26(1):25-36. PubMed ID: 9513074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
